Endo International plc and ADVANZ PHARMA Corp. Limited announced today that Endo International plc’s subsidiary Endo Ventures Limited has entered into a definitive agreement with Correvio International Sàrl entity, a subsidiary of ADVANZ PHARMA, to commercialize and distribute on an exclusive basis Xydalba® (dalbavancin hydrochloride) in Canada.
Under the terms of the agreement, Endo Ventures Limited will be responsible for the distribution, sales, marketing, medical affairs, pricing and reimbursement activities in Canada. Endo Venture Limited’s affiliate, Paladin Labs Inc., an operating company of Endo International plc, will perform those activities. ADVANZ PHARMA will be responsible for supplying the drug. Paladin Labs is targeting to launch the product in 2021. ADVANZ PHARMA will provide additional business updates as and when appropriate.
Xydalba® was approved by Health Canada in September 2018 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in adults caused by susceptible isolates of gram-positive microorganisms, including methicillin resistant Staphylococcus aureus (MRSA).